Ekso Bionics to Webcast Investor Day on December 6, 2016
November 30 2016 - 4:05PM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton
company, today announced it will host an Investor Day on December
6, 2016, in New York, NY. The presentation will begin at 8:00 a.m.
(Eastern Time) followed by a question and answer session, and is
expected to end at approximately 10:30 a.m., with product
demonstrations also included in the morning session. The
presentation will be webcast live and may be accessed via the Ekso
Bionics website at http://eksobionics.com under the Investor
section. Materials accompanying the presentation will also be
posted within this section under "News / Events" following the
event.
Presentations will be given by the following:
- Dylan Edwards, Ph.D., P.T., Director & Principal
Investigator, Burke Rehabilitation & Research; Principal
Investigator, WISE Study
- Frank Hyland, M.S., P.T. Vice President of Rehabilitation
Services and Administrator, Good Shepherd Rehabilitation
Hospital
- Russ Angold, President, Ekso Labs
For those unable to join the live webcast, a replay
will be available following the event and can be accessed on the
Ekso Bionics website at http://eksobionics.com under the
Investor section.
About Ekso Bionics® Ekso Bionics
is a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical, industrial and defense applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe, to providing
research for the advancement of R&D projects intended to
benefit U.S. defense capabilities. The company is headquartered in
the Bay Area and is listed on the Nasdaq Capital Market under the
symbol EKSO. For more information,
visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first exoskeleton cleared by
the FDA for use with stroke and spinal cord injuries from
L5 to C7. The Ekso GT with smart Variable Assist™ (marketed as
SmartAssist outside the U.S.) software is the only exoskeleton
available for rehabilitation institutions that can provide adaptive
amounts of power to either side of the patient’s body, challenging
the patient as they progress through their continuum of care. The
suit’s patented technology provides the ability to mobilize
patients earlier, more frequently and with a greater number of high
intensity steps. To date, this device has helped patients take more
than 55 million steps in over 120 rehabilitation institutions
around the world.
Media Contact:
Carrie Yamond/Rajni Dhanjani
212-867-1788
cyamond@lazarpartners.com
Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024